% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Nguyen:180222,
      author       = {M. T. N. Nguyen$^*$ and L.-J. Chen$^*$ and K. Trares$^*$
                      and H. Stocker$^*$ and B. Holleczek and K. Beyreuther and H.
                      Brenner$^*$ and B. Schöttker$^*$},
      title        = {{L}ong-term low-dose acetylsalicylic use shows protective
                      potential for the development of both vascular dementia and
                      {A}lzheimer's disease in patients with coronary heart
                      disease but not in other individuals from the general
                      population: results from two large cohort studies.},
      journal      = {Alzheimer's research $\&$ therapy},
      volume       = {14},
      number       = {1},
      issn         = {1758-9193},
      address      = {London},
      publisher    = {BioMed Central},
      reportid     = {DKFZ-2022-01173},
      pages        = {75},
      year         = {2022},
      note         = {#EA:C070#LA:C070#},
      abstract     = {No population-based cohort study investigated a potential
                      inverse association between long-term low-dose
                      acetylsalicylic acid (ASA) use and all-cause dementia and
                      its two most common sub-types Alzheimer's disease (AD) and
                      vascular dementia (VD) so far.Cox regression models with
                      inverse probability of treatment weighting to model the
                      underlying cardiovascular risk were used to assess the
                      associations of low-dose ASA use with all-cause dementia,
                      AD, and VD incidence in community-dwelling older adults from
                      the German ESTHER study (N = 5258) and the UK Biobank (N =
                      305,394). Inclusion criteria were age of 55 years or older
                      and completed drug assessment. Meta-analyses of the
                      individual participant data from the two prospective cohort
                      studies were performed.Four hundred seventy-six cases of
                      all-cause dementia, 157 cases of AD, and 183 cases of VD
                      were diagnosed over a median of 14.3 years of follow-up in
                      ESTHER. In the UK Biobank, 5584 participants were diagnosed
                      with all-cause dementia, 2029 with AD, and 1437 with VD over
                      a median of 11.6 years. The meta-analysis of both cohorts
                      revealed a weak reduction in hazards for all-cause dementia
                      (hazard ratio (HR) $[95\%$ confidence interval (CI)]: 0.96
                      [0.93 to 0.99]). The strongest protective effect of low-dose
                      ASA was observed in participants with coronary heart disease
                      (CHD) in both cohorts, and a significant interaction was
                      detected. In particular, in meta-analysis, a $31\%$
                      reduction in hazard for AD, $69\%$ for VD and $34\%$ for
                      all-cause dementia were observed (HR $[95\%$ CI]: 0.69 [0.59
                      to 0.80], 0.31 [0.27 to 0.35], 0.46 [0.42 to 0.50],
                      respectively). Furthermore, compared to non-users, users of
                      low-dose ASA for 10 years or longer (who likely use it
                      because they have CHD or a related diagnosis putting them at
                      an increased risk for cardiovascular events) demonstrated a
                      strong protective effect on all dementia outcomes,
                      especially for VD (HR $[95\%$ CI]: 0.48 [0.42 to 0.56])
                      whereas no protective associations were observed with
                      shorter low-dose ASA use.The protective potential of
                      low-dose ASA for all-cause dementia, AD, and VD seems to
                      strongly depend on pre-existing CHD and the willingness of
                      patients to take it for a minimum of ten years.},
      keywords     = {Aged / Alzheimer Disease: diagnosis / Cohort Studies /
                      Coronary Disease: complications / Dementia, Vascular:
                      complications / Humans / Middle Aged / Prospective Studies /
                      Risk Factors / Acetylsalicylic acid (Other) / Alzheimer’s
                      disease (Other) / Aspirin (Other) / Cohort study (Other) /
                      Coronary heart disease (Other) / Dementia (Other) /
                      Meta-analysis (Other) / Prevention (Other)},
      cin          = {C070},
      ddc          = {610},
      cid          = {I:(DE-He78)C070-20160331},
      pnm          = {313 - Krebsrisikofaktoren und Prävention (POF4-313)},
      pid          = {G:(DE-HGF)POF4-313},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:35624487},
      doi          = {10.1186/s13195-022-01017-4},
      url          = {https://inrepo02.dkfz.de/record/180222},
}